Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 15, 2022 Filed Nov 19, 2022 00:18 UTC Amendment |
BLAISE LUCILEPresident, Sleep & RC Business
|
Tax withholdingResMed Common Stock | 169 | $225.18 | $38,055.42 |
DisclosureSEC source: 0001127602-22-026089 · form4a.xml · nonDerivative · entry 1 BLAISE LUCILE · CIK 0001938112 · President, Sleep & RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,819 F1 · kind: Corrects transaction as disposition to issuer for tax withholding on scheduled vesting of Restricted Stock Units granted 11/14/2018. F2 · balance_after: Reflects corrected share beneficially owned. Read SEC document |
| November 11, 2022 Filed Nov 16, 2022 00:51 UTC |
Ghoshal KaushikPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 591 | $225.18 | $133,081.38 |
DisclosureSEC source: 0001127602-22-025669 · form4.xml · nonDerivative · entry 2 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,734 F2 · kind: Disposition to issuer for tax withholding on scheduled vesting of Restricted Stock Units granted 11/18/2021. F3 · balance_after: Includes 3.421 shares of ResMed stock purchased on October 31, 2022, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2022 Filed Nov 16, 2022 00:51 UTC |
Ghoshal KaushikPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 307 | $225.18 | $69,130.26 |
DisclosureSEC source: 0001127602-22-025669 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,325 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 11, 2022 Filed Nov 16, 2022 00:35 UTC |
Gill HarjitDirector
|
Tax withholdingResMed Common Stock | 41 | $225.18 | $9,232.38 |
DisclosureSEC source: 0001127602-22-025667 · form4.xml · nonDerivative · entry 1 Gill Harjit · CIK 0001759311 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,144 F1 · kind: Disposition to issuer for tax withholding on scheduled vesting of Restricted Stock Units granted 11/18/2021. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 23:54 UTC |
Douglas Robert AndrewPresident and COO
|
Tax withholdingResMed Common Stock | 760 | $225.18 | $171,136.80 |
DisclosureSEC source: 0001127602-22-025659 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,434 F2 · kind: Disposition to issuer for tax withholding on scheduled vesting of Restricted Stock Units granted 11/18/2021. F3 · balance_after: Includes 52.908 shares of ResMed stock purchased on October 31, 2022, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 23:54 UTC |
Douglas Robert AndrewPresident and COO
|
Tax withholdingResMed Common Stock | 945 | $225.18 | $212,795.10 |
DisclosureSEC source: 0001127602-22-025659 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,194 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2020. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 23:39 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 3,038 | $225.18 | $684,096.84 |
DisclosureSEC source: 0001127602-22-025657 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,024 F3 · kind: Disposition to issuer for tax withholding on scheduled vesting of Restricted Stock Units granted 11/18/2021. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 23:39 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 3,233 | $225.18 | $728,006.94 |
DisclosureSEC source: 0001127602-22-025657 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,062 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2020. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 23:39 UTC |
Farrell Michael J.Chief Executive Officer
|
Tax withholdingResMed Common Stock | 2,359 | $225.18 | $531,199.62 |
DisclosureSEC source: 0001127602-22-025657 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,295 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 23:26 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 279 | $225.18 | $62,825.22 |
DisclosureSEC source: 0001127602-22-025655 · form4.xml · nonDerivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,311 F3 · kind: Disposition to issuer for tax withholding on scheduled vesting of Restricted Stock Units granted 11/18/2021. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 23:26 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 337 | $225.18 | $75,885.66 |
DisclosureSEC source: 0001127602-22-025655 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,590 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/19/2020. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 23:26 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Tax withholdingResMed Common Stock | 450 | $225.18 | $101,331.00 |
DisclosureSEC source: 0001127602-22-025655 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,927 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 23:14 UTC |
FARRELL PETER CDirector
|
Tax withholdingResMed Common Stock | 128 | $225.18 | $28,823.04 |
DisclosureSEC source: 0001127602-22-025653 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,374 F1 · kind: Disposition to issuer for tax withholding on scheduled vesting of Restricted Stock Units granted 11/18/2021. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 16:56 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 4,880 | $220.83 | $1,077,650.40 |
DisclosureSEC source: 0001127602-22-025406 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lisette and Michael Farrell Foundation Disclosed balance after: 0 F3 · price: This transaction was executed in multiple trades at prices ranging from $220.67 $220.97. The price reported above reflects the weighted average sale price. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 16:56 UTC |
Farrell Michael J.Chief Executive Officer
|
GiftResMed Common Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025406 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lisette and Michael Farrell Foundation Disclosed balance after: 4,880 F2 · kind: Gift of shares transferred from The Lisette and Michael Farrell Family Trust, Mr. Farrell retains dispositive power over the gifted shares. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 16:56 UTC |
Farrell Michael J.Chief Executive Officer
|
GiftResMed Common Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-025406 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lisette and Michael Farrell Family Trust Disclosed balance after: 4,090 F1 · kind: Gift of shares transferred to The Lisette and Michael Farrell Foundation, Mr. Farrell retains dispositive power over remaining shares. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 22:03 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 4,000 | $212.02 | $848,067.60 |
DisclosureSEC source: 0001127602-22-025209 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,303 F1 · price: This transaction was executed in multiple trades at prices ranging from $212 to $212.04. The price reported above reflects the weighted average sale price. F2 · balance_after: Includes 30.50 shares of ResMed stock purchased on October 31, 2022, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 15:34 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,545 | $215.23 | $332,530.35 |
DisclosureSEC source: 0001127602-22-024941 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,334 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 21:23 UTC |
FARRELL PETER CDirector
|
GiftResMed Common Stock | 4,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024789 · form4.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,502 F2 · kind: Represents a gift of shares to Bank of America, N.A. Successor Trustee of Peter C. Farrell Charitable Remainder Unitrust. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 21:23 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 9,050 | $221.98 | $2,008,877.37 |
DisclosureSEC source: 0001127602-22-024789 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,052 F1 · price: This transaction was executed in multiple trades at prices ranging from $217.65 to $224.11. The price reported above reflects the weighted average sale price. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 20:18 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-024077 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,240 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 20:18 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $214.58 | $1,217,723.34 |
DisclosureSEC source: 0001127602-22-024077 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,570 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $213.43 to $215.62. The price reported above reflects the weighted average sale price. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 20:18 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-024077 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 14, 2022 Filed Oct 17, 2022 23:25 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock Options · Derivative | 16,888 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-22-023989 · form4.xml · derivative · entry 6 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,032 Underlying: ResMed Common Stock · 16,888 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| October 14, 2022 Filed Oct 17, 2022 23:25 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock Options · Derivative | 1,145 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-22-023989 · form4.xml · derivative · entry 5 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,920 Underlying: ResMed Common Stock · 1,145 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| October 14, 2022 Filed Oct 17, 2022 23:25 UTC |
Douglas Robert AndrewPresident and COO
|
SaleResMed Common Stock | 11,355 | $215.09 | $2,442,298.12 |
DisclosureSEC source: 0001127602-22-023989 · form4.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,086 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $213.62 to $217.36. The price reported above reflects the weighted average sale price. Read SEC document |
| October 14, 2022 Filed Oct 17, 2022 23:25 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock | 16,888 | $58.24 | $983,557.12 |
DisclosureSEC source: 0001127602-22-023989 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 14, 2022 Filed Oct 17, 2022 23:25 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock | 1,145 | $58.24 | $66,684.80 |
DisclosureSEC source: 0001127602-22-023989 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 15:35 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,545 | $220.19 | $340,193.55 |
DisclosureSEC source: 0001127602-22-023624 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,879 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 23:18 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock Options · Derivative | 16,888 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-22-022565 · form4.xml · derivative · entry 7 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,065 Underlying: ResMed Common Stock · 16,888 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 23:18 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock Options · Derivative | 1,145 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-22-022565 · form4.xml · derivative · entry 6 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,953 Underlying: ResMed Common Stock · 1,145 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 23:18 UTC |
Douglas Robert AndrewPresident and COO
|
GiftResMed Common Stock | 1,287 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-022565 · form4.xml · nonDerivative · entry 5 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 227,708 F3 · kind: Gift of shares to Fidelity Charitable, a donor advised fund. Mr. Douglas has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 23:18 UTC |
Douglas Robert AndrewPresident and COO
|
SaleResMed Common Stock | 6,000 | $232.38 | $1,394,280.00 |
DisclosureSEC source: 0001127602-22-022565 · form4.xml · nonDerivative · entry 4 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 228,995 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $232.45 to $232.91. The price reported above reflects the weighted average sale price. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 23:18 UTC |
Douglas Robert AndrewPresident and COO
|
SaleResMed Common Stock | 11,189 | $232.51 | $2,601,583.48 |
DisclosureSEC source: 0001127602-22-022565 · form4.xml · nonDerivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,408 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $232.45 to $232.91. The price reported above reflects the weighted average sale price. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 23:18 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock | 16,888 | $58.24 | $983,557.12 |
DisclosureSEC source: 0001127602-22-022565 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 23:18 UTC |
Douglas Robert AndrewPresident and COO
|
Exercise / conversionResMed Common Stock | 1,145 | $58.24 | $66,684.80 |
DisclosureSEC source: 0001127602-22-022565 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 16:19 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-022621 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,915 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 16:19 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $228.96 | $1,299,336.08 |
DisclosureSEC source: 0001127602-22-022621 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,570 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $225.93 to $233.73. The price reported above reflects the weighted average sale price. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 16:19 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-022621 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 20:54 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,545 | $216.92 | $335,141.40 |
DisclosureSEC source: 0001127602-22-022156 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,424 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 19:10 UTC |
Ghoshal KaushikPresident, SaaS Business
|
GrantResMed Common Stock | 3,366 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-021425 · form4.xml · nonDerivative · entry 1 Ghoshal Kaushik · CIK 0001881922 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,628 F1 · kind: Represents performance-based restricted stock units granted on November 18, 2021. The shares were earned on August 18, 2022, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. F2 · balance_after: Includes 91.7782 shares of ResMed stock purchased on April 29, 2022, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 19:09 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 1,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-021424 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,969 F1 · kind: Represents performance-based restricted stock units granted on November 18, 2021. The shares were earned on August 18, 2022, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 19:08 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 3,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-021423 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,273 F1 · kind: Represents performance-based restricted stock units granted on November 18, 2021. The shares were earned on August 18, 2022, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 19:07 UTC |
Douglas Robert AndrewPresident and COO
|
GrantResMed Common Stock | 4,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-021422 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,564 F1 · kind: Represents performance-based restricted stock units granted on November 18, 2021. The shares were earned on August 18, 2022, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. F2 · balance_after: Includes 61.1855 shares of ResMed stock purchased on April 29, 2022, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 19:06 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 17,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-021421 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,570 F1 · kind: Represents performance-based restricted stock units granted on November 18, 2021. The shares were earned on August 18, 2022, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 16:29 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,675 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-021156 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,590 Underlying: ResMed Common Stock · 5,675 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 16:29 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,675 | $238.09 | $1,351,165.86 |
DisclosureSEC source: 0001127602-22-021156 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,260 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $235.22 to $240.41. The price reported above reflects the weighted average sale price. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 16:29 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,675 | $57.76 | $327,788.00 |
DisclosureSEC source: 0001127602-22-021156 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 16:11 UTC |
Sandercock BrettChief Financial Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 2,500 | $0.00 Strike: $57.76 | $0.00 |
DisclosureSEC source: 0001127602-22-020860 · form4.xml · derivative · entry 3 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 2,500 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 16:11 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $240.66 | $601,650.00 |
DisclosureSEC source: 0001127602-22-020860 · form4.xml · nonDerivative · entry 2 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,426 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.